The Phase I CHRYSALIS trial, which evaluated amivantamab in 362 patients with EGFR exon 20 insertion-mutated NSCLC, reported an incidence of 3.3% for all-grade pneumonitis, with 0.7% of patients experiencing grade 3 or higher events [31,65]. This evidence concerns the gene EGFR and pneumonitis.